RE: FIT biotech3 May 2019 16:18
Agreed nomlungo ..Fits nicely within my interpretation of Valirx mission statement...................
For UK Medical Media
First of its kind study to evaluate the effectiveness of
combining established tolerable, generic medicines in the
treatment of cancer
METRICS study investigates a new treatment route for patients for whom standard
treatments are not viable or may benefit from adding this treatment
London, UK, 2nd September , 2014 – The Care Oncology Clinic, based in Harley Street, London
announced today that it is recruiting patients onto a first-of-its-kind medical study to evaluate the
effectiveness and tolerability of a unique combination of existing medicines in slowing the growth
rate of tumours.
The open-label, observational METRICS study (Study of the Safety, Tolerability and Efficacy of
Metabolic Treatments of Cancer), supported by The SEEK Group, aims to help patients who have
been diagnosed with cancer and are unable to tolerate, see benefit from or have access to existing
cancer therapies, or who may benefit from adding this treatment to the standard of care.
The METRICS study will examine the effect of tailored combinations of existing therapies, such as
metformin, statins, doxycycline, mebendazole and ibuprofen, on the cancer cells’ metabolism.
METRICS will also assess the potential of this regimen to reduce tumour growth, with a primary
outcome measure of progression-free survival over five years, alongside secondary quality of life and
tumour response outcomes. METRICS builds on existing, published studies2-31 that demonstrate the
potential of these metabolic therapies to inhibit tumour growth as monotherapy.
Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial
College and Imperial College Healthcare NHS Trust, is leading the study and comments, “The
METRICS study provides another option for those people for whom standard cancer treatment
regimens are not viable, tolerable, available or providing any benefit on a stand-alone basis. The
medicines prescribed in the study are well-established, having been used by a large number of people
over a long period of time, with known side effects. The medicines have also been shown to reduce
cancer growth rates. By studying these treatments in combination, it is hoped we will see a slowing of
or ******ing of cancer growth rates above and beyond using the medicines on their own at the same
time as providing the patient with an improved quality of life”.
Sign In
Follow the stocks
